Azactam

Aztreonam is a potent monobactam antibacterial agent primarily used to treat serious infections caused by Gram-negative aerobic bacteria, including Pseudomonas aeruginosa, in both adult and pediatric patients.

The dosage of Aztreonam is determined by the healthcare provider based on the severity of the infection, the site of the infection, and the patient's renal function. According to the FDA-approved prescribing information, the standard adult dosages are as follows:

• Urinary Tract Infections: 500 mg or 1 gram administered every 8 or 12 hours.
• Moderately Severe Systemic Infections: 1 gram or 2 grams administered every 8 or 12 hours.
• Severe or Life-Threatening Infections: 2 grams administered every 6 or 8 hours. The maximum recommended dose is 8 grams per day.
• Inhalation for Cystic Fibrosis: The typical dose is 75 mg administered three times daily for a 28-day cycle, followed by 28 days off the medication.

For intramuscular (IM) administration, doses greater than 1 gram are generally not recommended; instead, the intravenous (IV) route should be used for higher doses.

Aztreonam is approved for use in pediatric patients for the treatment of various Gram-negative infections. The dosage is typically calculated based on the child's body weight:

• Infants and Children (>1 month old): The standard dose is 30 mg/kg administered every 6 or 8 hours. For very severe infections in children older than 2 years, doses up to 50 mg/kg every 6 hours may be used, not to exceed the maximum adult dose of 8 grams per day.
• Neonates (<1 month old): Dosing in newborns is specialized and depends on gestational age and birth weight. Healthcare providers typically use 30 mg/kg every 8 to 12 hours.

Renal Impairment

Because Aztreonam is primarily cleared by the kidneys, dosage adjustments are critical for patients with reduced renal function to prevent drug accumulation and toxicity.

• Creatinine Clearance (CrCl) 10-30 mL/min: After an initial loading dose of 1 or 2 grams, the maintenance dose is typically reduced by 50%.
• CrCl <10 mL/min (including dialysis patients): After the loading dose, the maintenance dose is typically reduced to 25% of the standard dose. For patients on hemodialysis, a supplemental dose (1/8 of the initial dose) may be given after each dialysis session.

Hepatic Impairment

While Aztreonam is not extensively metabolized by the liver, patients with severe hepatic impairment should be monitored closely. However, standard labeling does not currently mandate specific dosage reductions for liver disease alone, as renal clearance remains the primary elimination pathway.

Elderly Patients

Older adults are more likely to have decreased renal function. Healthcare providers should assess the glomerular filtration rate (GFR) in elderly patients and adjust the dose of Aztreonam accordingly. Monitoring kidney function throughout therapy is highly recommended in this population.

Aztreonam is administered by healthcare professionals in a clinical setting via injection or infusion.

• Intravenous (IV) Infusion: The drug is usually infused over a period of 20 to 60 minutes. It can also be given as a slow IV bolus (injection) over 3 to 5 minutes.
• Intramuscular (IM) Injection: The injection should be made deep into a large muscle mass (such as the gluteus maximus).
• Inhalation: If using the inhaled form (Cayston), it must be used only with the Altera Nebulizer System. Patients are usually instructed to use a bronchodilator before the Aztreonam dose to open the airways.
• Storage: Reconstituted solutions for injection should be used promptly. If stored at room temperature, they are generally stable for 24 hours; if refrigerated, they may last up to 7 days, depending on the diluent used.

In a hospital setting, your nursing staff will manage your dosing schedule. If you are using the inhaled version at home and miss a dose, take it as soon as you remember. However, if it is nearly time for your next dose, skip the missed dose and resume your regular schedule. Do not double the dose to catch up.

An overdose of Aztreonam is rare since it is usually administered by medical professionals. However, symptoms of overdose may include an exacerbation of side effects or seizures. In the event of a suspected overdose, emergency measures include supportive care and, if necessary, hemodialysis or peritoneal dialysis to help remove the drug from the bloodstream.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop the medication early without medical guidance, as this can lead to antibiotic resistance.

Aztreonam is generally well-tolerated, but like all antibiotics, it can cause side effects. The most frequently reported adverse reactions occur at the site of administration:

• Injection Site Reactions: Approximately 2% to 10% of patients experience localized pain, redness, or swelling at the IV or IM injection site. This is usually transient and resolves shortly after the infusion is complete.
• Gastrointestinal Distress: Mild diarrhea, nausea, and vomiting are common. These symptoms occur as the antibiotic alters the balance of bacteria in the gut. They typically last only as long as the treatment duration.
• Dermatologic Reactions: A mild skin rash or itching (pruritus) may occur. If the rash is mild and not accompanied by swelling or difficulty breathing, it may not require discontinuation of the drug, but it must be reported to a doctor.

Aztreonam should only be used to treat infections that are proven or strongly suspected to be caused by susceptible Gram-negative bacteria. Using it for viral infections (like the common cold) or Gram-positive infections will not be effective and increases the risk of antibiotic resistance. Patients must complete the full course of therapy even if they feel better after the first few doses.

No FDA black box warnings for Aztreonam.

• Allergic Reactions / Anaphylaxis Risk: Before starting Aztreonam, your doctor must know if you have ever had an allergic reaction to penicillins, cephalosporins, or carbapenems. While Aztreonam is structurally different and often safe for these patients, cross-reactivity has been reported, particularly with the cephalosporin antibiotic Ceftazidime, which shares a similar side chain. If an allergic reaction occurs, the drug must be stopped immediately and emergency treatment (epinephrine, oxygen, IV fluids) initiated.

There are no absolute drug-drug contraindications where Aztreonam must never be used with another agent. However, certain combinations are avoided unless absolutely necessary due to predictable risks.

• Aminoglycosides (e.g., Gentamicin, Amikacin): These are often used in combination with Aztreonam for a synergistic effect against Pseudomonas aeruginosa. While effective, this combination increases the risk of nephrotoxicity (kidney damage) and ototoxicity (hearing loss). Renal function and hearing should be monitored closely.
• Cefazolin and Other Cephalosporins: Some studies suggest that using high doses of cephalosporins alongside other beta-lactams might increase the risk of kidney strain. Monitoring of renal parameters is advised.
• Oral Anticoagulants (e.g., Warfarin)

Aztreonam is strictly contraindicated in patients with a known hypersensitivity to Aztreonam or any component of the formulation. An absolute contraindication means the drug should never be used because the risk of a life-threatening reaction far outweighs any potential benefit.

• Mechanism: In sensitized individuals, the immune system recognizes the aztreonam molecule as a foreign invader, triggering a massive release of histamine and other inflammatory mediators. This can lead to anaphylactic shock, airway obstruction, and death.

Relative contraindications are conditions where the drug should be used with extreme caution and only if the benefits clearly justify the risks:

• Severe Penicillin or Cephalosporin Allergy: While Aztreonam is often used as a safe alternative for these patients, those with a history of anaphylactic

Aztreonam is classified as FDA Pregnancy Category B. This means that animal reproduction studies have failed to demonstrate a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women.

• Trimester-Specific Risks: Data from animal studies (rats and rabbits) using doses up to 15 times the human dose showed no evidence of embryotoxicity or teratogenicity (birth defects).
• Clinical Use: Aztreonam should be used during pregnancy only if clearly needed. Healthcare providers typically weigh the severity of the maternal infection against the theoretical risk to the fetus. It is generally considered one of the safer options for serious Gram-negative infections in pregnant patients when other first-line agents are inappropriate.

Aztreonam is excreted in human breast milk in very low concentrations (less than 1% of the maternal serum concentration).

Aztreonam is a bactericidal antibiotic that acts by inhibiting bacterial cell wall synthesis. Its molecular target is Penicillin-Binding Protein 3 (PBP3), an enzyme located on the inner membrane of Gram-negative bacteria. By covalently binding to the active site of PBP3, Aztreonam prevents the cross-linking of peptidoglycan chains. This results in the inhibition of septum formation during bacterial cell division, leading to filamentation and eventual osmotic lysis of the cell. Its unique monobactam structure makes it highly resistant to many beta-lactamases, including metallo-beta-lactamases, though it remains vulnerable to certain ESBLs.

The efficacy of Aztreonam is time-dependent. This means that the clinical outcome is best predicted by the amount of time the concentration of the drug in the blood remains above the Minimum Inhibitory Concentration (MIC) of the target bacteria (T > MIC). For optimal killing, the drug concentration should exceed the MIC for at least 40-60% of the dosing interval. There is a minimal post-antibiotic effect (PAE) against Gram-negative bacilli, meaning the drug stops working quickly once levels drop below the MIC.